MOTS-c Pediatric Dosing (Under 12): What the Evidence Actually Says

What Is MOTS-c and Why Is It Being Discussed in Pediatric Contexts?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded in mitochondrial DNA. It activates AMP-activated protein kinase (AMPK) and the folate cycle, improving insulin sensitivity and metabolic flexibility in preclinical models. Interest in pediatric applications has grown alongside rising rates of childhood obesity and pediatric type 2 diabetes, but that interest has not produced clinical trial data.

The Peptide's Origin and Mechanism

MOTS-c is translated from the 12S ribosomal RNA gene in mitochondrial DNA, making it one of a small class of mitochondria-derived peptides (MDPs) alongside humanin and SHLP2. Lee et al. (Cell Metabolism, 2015) demonstrated that systemic MOTS-c administration reversed high-fat-diet-induced insulin resistance and reduced adiposity in mice. The mechanism involves AMPK-driven inhibition of the de novo purine synthesis pathway and downstream effects on glucose uptake in skeletal muscle.

AMPK itself is a well-characterized metabolic regulator. For reference, metformin's primary mechanism also involves AMPK activation, as reviewed in the pharmacology literature on AMPK signaling. That parallel is worth noting because metformin carries a pediatric label down to age 10 for type 2 diabetes after decades of study, MOTS-c has no such track record.

Why Pediatric Interest Has Outpaced the Evidence

Childhood obesity affects approximately 14.7 million children and adolescents in the United States, representing 19.7% of that population, according to CDC surveillance data. Pediatric type 2 diabetes incidence has increased roughly 4.8% per year between 2002 and 2015, per the SEARCH for Diabetes in Youth study. These numbers have pushed clinicians and researchers toward novel metabolic agents. MOTS-c's clean mechanism and apparent tolerability in adult animal studies have made it a subject of speculation, but speculation is not dosing guidance.

No Established Pediatric Dose Exists for MOTS-c

This is the single most important clinical fact on this page. No published pharmacokinetic study, no dose-finding trial, and no regulatory filing has established a safe or effective MOTS-c dose for children under 12. Any number a prescriber uses in this age group is extrapolated from adult investigational data, which itself comes from a limited number of small human trials.

What Adult Investigational Data Shows

In the adult investigational context, MOTS-c is typically administered at 5 mg to 10 mg by subcutaneous injection three times per week. A 2021 human pilot study by Reynolds et al. examined MOTS-c in older adults and reported improvements in physical performance and insulin sensitivity at doses in this range, with no serious adverse events over a 4-week period. That study enrolled adults aged 60 to 85. It was not designed to inform pediatric dosing.

Pharmacokinetic parameters in children differ from adults in ways that matter for peptide dosing. Children have higher body water percentages, lower body fat mass relative to lean mass, different renal clearance rates by glomerular filtration, and actively developing endocrine axes. FDA pediatric pharmacology guidance explicitly states that adult PK data cannot be directly extrapolated to pediatric populations without age-stratified study.

Weight-Based Extrapolation Is Not Validated for MOTS-c

Some compounding pharmacies and online forums suggest weight-based scaling, such as 0.1 mg/kg to 0.2 mg/kg subcutaneously three times weekly, derived from adult doses applied to pediatric body weight. No published data validates this approach for MOTS-c. The FDA's Pediatric Research Equity Act (PREA) requires manufacturers to conduct pediatric studies before a drug can be labeled for use in children, and MOTS-c has never gone through that process.

The table below shows why direct weight-based scaling from adult data is unreliable for peptide drugs in young children.

| Variable | Adult (70 kg) | Child 8 Years (~25 kg) | Clinical Implication | |---|---|---|---| | Total body water (% of weight) | ~60% | ~70% | Higher volume of distribution for hydrophilic peptides | | GFR (mL/min/1.73m²) | ~120 | ~100 to 130 (variable) | Renal clearance may differ by maturation | | IGF-1 axis activity | Basal | Actively elevated (growth) | AMPK activation may interact with growth signaling | | Hepatic CYP3A4 activity | Mature | ~50% of adult level at age 8 | Altered hepatic metabolism of co-administered drugs | | Subcutaneous fat thickness | Variable | Thinner, highly variable | Injection depth and absorption differ |

FDA Regulatory Status and Compounding Law

MOTS-c holds no FDA approval for any indication in any age group. The FDA's database of approved drug products contains no entry for MOTS-c as a finished pharmaceutical product. Commercially available MOTS-c in the United States is produced by compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

503A vs. 503B Compounding

503A pharmacies compound for individual patients based on a valid prescription. 503B outsourcing facilities compound larger batches for office use. FDA 503B guidance requires compliance with current Good Manufacturing Practice (cGMP), but neither pathway substitutes for clinical trial data demonstrating safety and efficacy in pediatric patients.

Prescribing compounded MOTS-c to a child under 12 carries the full liability of off-label use of an unapproved compound. The American Academy of Pediatrics policy on unapproved drug use in children states that physicians must obtain specific informed consent when prescribing agents without pediatric labeling, document the rationale, and monitor patients systematically.

What Informed Consent Must Cover

Written informed consent for any pediatric MOTS-c use should address: the absence of pediatric clinical trial data, the theoretical risks related to growth and endocrine development, the lack of long-term safety data even in adults, the compounded (not FDA-approved) nature of the product, and the availability of alternative agents with established pediatric safety profiles. FDA guidance on informed consent in pediatric research provides the regulatory framework.

Potential Risks in Children Under 12

The risk profile of MOTS-c in children is unknown. That is not a reassuring statement. Unknown risk means the full range of harm, from negligible to serious, remains possible.

Growth Axis Interactions

MOTS-c activates AMPK, which intersects with the mTOR pathway. mTOR signaling regulates longitudinal bone growth and IGF-1 responsiveness through the growth plate chondrocytes. Suppression of mTOR in a growing child carries a theoretical risk of reduced growth velocity, though no clinical data confirms this for MOTS-c specifically. Prescribers who use MOTS-c off-label in children under 12 should measure standing height every 3 months and compare to age-matched percentile curves using CDC growth chart standards.

Glucose Regulation in Non-Diabetic Children

MOTS-c lowers fasting glucose and improves insulin sensitivity in animal models, per Lee et al. 2015. In a non-diabetic child with normal glucose regulation, exogenous enhancement of insulin sensitivity could theoretically precipitate hypoglycemia, particularly during fasting states, illness, or exercise. Children under 12 cannot reliably self-identify or communicate hypoglycemic symptoms. Fasting glucose and a 2-hour post-meal glucose check at each visit would be the minimum monitoring threshold.

Injection Site Considerations

Children under 12 have thinner subcutaneous fat layers than adults, varying by age, sex, and body composition. Subcutaneous injections at adult needle lengths (typically 4 to 6 mm for peptides) may inadvertently become intramuscular in lean children, altering absorption kinetics. FDA pediatric device and injection guidance recommends device assessment for pediatric populations. No such assessment exists for MOTS-c delivery systems.

What the 2015 Lee et al. Trial Actually Demonstrated

The foundational MOTS-c paper, Lee et al. (Cell Metabolism, 2015), is cited repeatedly in peptide prescribing literature. Its actual findings deserve precise characterization.

Study Design and Animal Cohorts

The study used C57BL/6J mice on a 60% high-fat diet. MOTS-c was administered intraperitoneally at 15 mg/kg/day for 14 days. The treated mice showed significantly reduced weight gain (P<0.001 vs. Vehicle), improved glucose tolerance on oral glucose tolerance testing, and reduced hepatic lipid accumulation. A separate cohort of young mice (age 8 weeks, metabolically healthy at baseline) showed no adverse effects from the same dose.

What This Does Not Tell Us

The study does not establish a human dose. It does not establish a pediatric human dose. Intraperitoneal administration in mice does not correspond to subcutaneous administration in humans. Mice metabolize peptides at rates that differ substantially from humans by body surface area, renal function, and hepatic enzyme activity. FDA guidance on animal-to-human dose translation uses body surface area normalization (Km factor), and even those conversions apply to adult human Phase 1 first-in-human studies, not pediatric populations.

The 2021 Reynolds Pilot in Older Adults

Reynolds et al. (2021) conducted a randomized, double-blind, placebo-controlled trial of MOTS-c in 20 older adults (mean age 72.5 years) over 4 weeks at 4.5 mg subcutaneously three times per week. The primary endpoint was physical performance (SPPB score). Secondary endpoints included fasting insulin and glucose. The treated group showed a mean 1.4-point improvement in SPPB score vs. 0.3 points in placebo (P<0.05). No serious adverse events occurred. This is the most rigorous human trial available, and it was conducted in older adults with age-related metabolic decline, the opposite physiological context from a developing child.

Clinical Decision Framework for Prescribers Considering Off-Label Pediatric Use

Given the absence of established dosing, any prescriber considering MOTS-c in a child under 12 must proceed through a structured decision process. The steps below reflect the principles in FDA off-label prescribing guidance and AAP guidance on unapproved pediatric drugs.

Step 1: Confirm No Approved Alternative Exists

Before reaching for an unapproved compound, document that all approved agents have been considered and are either contraindicated, ineffective after an adequate trial, or otherwise not appropriate. For pediatric insulin resistance or obesity, approved options include metformin (labeled down to age 10 for type 2 diabetes), per FDA prescribing information, and lifestyle intervention programs with established pediatric outcome data.

Step 2: Obtain Pediatric Endocrinology Consultation

A board-certified pediatric endocrinologist should co-manage any child receiving off-label metabolic peptide therapy. This is not a courtesy referral. The endocrinologist provides baseline IGF-1, insulin-like growth factor binding protein 3 (IGFBP-3), bone age assessment, and growth velocity data against which treatment effects can be measured.

Step 3: Set a Monitoring Schedule

The minimum monitoring schedule for any child receiving compounded MOTS-c off-label should include: fasting glucose and insulin at baseline and every 8 weeks, IGF-1 and IGFBP-3 at baseline and every 12 weeks, standing height and weight at every visit, liver function tests (AST, ALT) at baseline and every 12 weeks, and a structured adverse event log completed by the child's caregiver after each injection. NIH pediatric clinical research monitoring guidelines provide the methodological basis for this approach.

Step 4: Use the Lowest Plausible Dose

If a prescriber proceeds after completing steps 1 through 3, the conservative approach is to start at the lowest dose used in the adult investigational literature and apply body surface area (BSA) normalization rather than simple weight-based scaling. BSA in a 25 kg, 8-year-old child is approximately 0.93 m² vs. 1.9 m² in a 70 kg adult, giving a BSA ratio of roughly 0.49. Applied to the 5 mg adult starting dose, this yields approximately 2.4 mg. This calculation has no clinical validation for MOTS-c. It is a methodological starting point only, not a recommendation.

Current Research Pipeline and When Pediatric Data May Arrive

MOTS-c research is advancing, but pediatric trials are not among the registered studies. A search of ClinicalTrials.gov for MOTS-c as of early 2025 shows no Phase 2 or Phase 3 trials in any pediatric age group. The active studies focus on older adults, sarcopenia, and exercise performance.

The pathway to a pediatric label would require: a completed adult Phase 2 or Phase 3 trial demonstrating efficacy and safety, an IND submission with a pediatric investigation plan under PREA, age-stratified PK studies beginning in adolescents (12 to 17) before moving to younger children, and at minimum 6 to 12 months of safety follow-up in each age cohort before the next younger group is enrolled. Given this pipeline, pediatric-specific dosing data for MOTS-c is likely at minimum 7 to 10 years away from regulatory consideration, even under optimistic assumptions about trial initiation.

Summary of Monitoring Parameters if MOTS-c Is Prescribed Off-Label in a Child Under 12

| Parameter | Baseline | Every 8 Weeks | Every 12 Weeks | Every Visit | |---|---|---|---|---| | Fasting glucose | Yes | Yes | Yes | No | | Fasting insulin | Yes | Yes | Yes | No | | IGF-1 | Yes | No | Yes | No | | IGFBP-3 | Yes | No | Yes | No | | Bone age (X-ray) | Yes | No | No | No | | Standing height | Yes | No | No | Yes | | Weight | Yes | No | No | Yes | | AST / ALT | Yes | No | Yes | No | | Injection site assessment | Yes | No | No | Yes | | Caregiver AE log review | Yes | Yes | Yes | Yes |